NOT-AR-21-027: Notice of NIAMS Withdrawal from Participation inPAR-19-173 "Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R21 Clinical Trial Not Allowed)"

Notice of NIAMS Withdrawal from Participation in PAR-19-173 "Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R21 Clinical Trial Not Allowed)"

Notice Number:

NOT-AR-21-027

Key Dates

Release Date:

July 27, 2021

Related Announcements

PAR-19-173 - Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R21 Clinical Trial Not Allowed)

Issued by

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Purpose

This Notice is to inform the applicant community that, effective immediately, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) withdraws its participation in Funding Opportunity Announcement (FOA), PAR-19-173 "Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R21 Clinical Trial Not Allowed).

Inquiries

Please direct all inquiries to:

Marie Mancini, PhD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Phone: 301-594-5032
Email: [email protected]